Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies

Sheikh, Aziz; Nurmatov, Ulugbek; Venderbosch, Iris; Bischoff, Erik

doi:10.4104/pcrj.2011.00071

Cited by 45 publications

(39 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, in recent oral and sublingual immunotherapy trials, it is typical to administer doses on a daily basis and to escalate dosing over a period of 4-6 months (7,(24)(25). We had anticipated that a more rapid escalation and weekly dosing would be tolerated using this modified product, and although we do not know that a different approach to dosing would be beneficial, it is certainly possible that it would be.…”

Section: Discussionmentioning

confidence: 99%

“…Current treatment relies on strict dietary avoidance and ready access to injectable epinephrine. Traditional subcutaneous immunotherapy has proven unsafe for peanut allergy (5) and although oral and sublingual immunotherapy have shown some promise for peanut and other food allergens (6)(7)(8)(9), these approaches have the potential for significant adverse reactions (10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Phase 1 Study of Heat/Phenol Killed, E. coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the Treatment of Peanut Allergy

Wood

Stablein

Henning

et al. 2012

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Phase 1 Study of Heat/Phenol Killed, E. coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the Treatment of Peanut Allergy

Wood

Stablein

Henning

et al. 2012

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…The first studies of OIT for peanut allergy were uncontrolled and performed in the United States [56][57] and Europe, [58][59] and these studies showed promising results. A systematic review of OIT for peanut allergy by Sheikhet [60] discussed findings from these studies and 3 abstract articles. Most recently, 1 controlled study was performed in the United States and another uncontrolled one in Europe.…”

Section: Studies Of Oit For Peanut and Tree Nut Allergiesmentioning

confidence: 99%

The Progress of Food Allergy Concept, Classifications and Diagnosis

Kamal-Alahmad¹

2016

IJNFS

View full text Add to dashboard Cite

Food allergies, defined as an immune response to food proteins, affect as many as 8% of young children and 5% of adults in most countries, and their prevalence appears to be rising like all allergic diseases, In addition to well-recognized urticaria and anaphylaxis triggered by IgE antibody-mediated immune responses. Food allergy is a rapidly growing public health concern because of its increasing prevalence and life-threatening potential. Food allergic reaction can be further subdivided into IgE mediated and non IgE mediated. The diagnosis of food allergy is made from the history, supported by investigations and by responses to avoidance of specific food triggers. So in this work we want to introduce some concepts in food allergy such as classification of allergic and diagnosis of food triggers and finally how to manage this problem and minimize the prevalence of food allergy.

show abstract

“…En la última revisión sistemáti-ca de seis estudios publicada se concluye que para muchos pacientes esta inmunoterapia les permite incrementar el umbral de tolerancia durante el tratamiento, si bien las reacciones adversas fueron frecuentes durante la inmunoterapia, siendo la mayoría leves aunque algunas con riesgo vital. En conclusión, aunque parece ofrecer resultados prometedores, se recomienda realizar más estudios para demostrar la eficacia y coste-beneficio especialmente a largo plazo, debiéndose realizar estudios más potentes que permitan recomendar su uso clínico 47 . Por las limitaciones que hemos mencionado, se están explorando nuevas formas de administrar la inmunoterapia de forma que mejore su seguridad y eficacia.…”

Section: Aplicación Para El Tratamiento De Alergia Alimentariaunclassified

Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas

Ferrer

Sánz

Gastaminza

et al. 2012

Anales Sis San Navarra

View full text Add to dashboard Cite

resuMenLa inmunoterapia para el tratamiento de enfermedades alérgicas implica ciertas desventajas, que pueden ser reducidas si se emplean adyuvantes adecuados, que sean capaces de amplificar la respuesta inmune con un efecto alergénico mínimo. En ese contexto, las formas farmacéuticas más prometedoras para aumentar la eficacia y seguridad de la inmunoterapia, parecen ser las micro y nanopartículas, de polímeros biodegradables y liposomas. En esta revisión describimos estudios previos de nuestro grupo en los que empleamos como adyuvante nanopartículas Gantrez® AN y demostramos su capacidad de estimular el sistema inmune. Empleamos dos tipos de nanopartículas, con y sin lipopolisacárido de Brucella ovis como inmunomodulador en un modelo de ratón alérgico a L. perenne. Encontramos que los ratones sensiblizados a Phleum cuando recibían inmunoterapia con nanopartículas Lolium-Gantrez® estaban protegidos de la anafilaxia inducida por el alérgeno tanto en las tasas de mortalidad como en los niveles de MCP-1. Probamos asimismo estas formulaciones por vía oral en un modelo animal sensibilizado a ovoalbúmina y comprobamos que les protegía también del shock anafiláctico.Palabras clave. Inmunoterapia. Alergia. Nanopartícu-las. Micropartículas. AbstrActSpecific immunotherapy involves certain drawbacks which could be minimized by the use of appropriate adjuvants, capable of amplifying the right immune response with minimal side effects. In this context, we review different types of immunotherapy vehicles and coadyuvants. We describe previous studies by our group in which we demonstrated the adjuvant capacity of Gantrez® AN nanoparticles, which can effectively enhance the immune response. We employed two types of nanoparticles (with and without LPS of Brucella ovis as immunomodulator) within capsulated ovoalbumin and Lollium perenne extract, tested on a model of mice sensitized to this allergenic mixture. In the challenge experiment involving the sensitized mice, differences in the mortality rate and in the MCP-1 levels were found between the treated groups and the control. Under the experimental conditions of this model of mice pre-sensitized to L. perenne, Gantrez®AN nanoparticles appeared to be a good strategy for immunotherapy. We finally tested these carriers administered by the oral route and found that they were able to protect a model of mice sensitized to ovalbumin from anaphylactic shock.

show abstract

Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies

Cited by 45 publications

References 33 publications

A Phase 1 Study of Heat/Phenol Killed, E. coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the Treatment of Peanut Allergy

A Phase 1 Study of Heat/Phenol Killed, E. coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the Treatment of Peanut Allergy

The Progress of Food Allergy Concept, Classifications and Diagnosis

Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas

Contact Info

Product

Resources

About